neurodAIgnostics

neurodAIgnostics operates at the intersection of healthcare, neuroscience, software, and telehealth, with a focused product concept: AI-assisted cognitive assessments and test scoring for neuropsychologists. That specialization distinguishes its stated offering from broad digital-health platforms, though the available company profile does not establish a direct competitor set or provide comparative performance data. Its described roots in University of Zurich research and emphasis on clinical workflows suggest a research-informed, clinician-oriented approach rather than a general-purpose AI product. Recognition on Venturelab’s Swiss National Medtech Team 2026 provides visibility and access to investors and partners, including through a Boston roadshow, but does not by itself demonstrate commercial adoption. Evidence about regulatory status, clinical validation, customer numbers, pricing, and deployment scale is limited. As a result, its position is best characterized as an early-stage specialist developing tools for cognitive assessment, with differentiation centered on applying AI to an established clinical workflow. No distinct named competitors can be reliably identified from the available profile.

The company’s profile points to an early-stage trajectory built around research-derived product development, a small team, grant support, and increasing ecosystem visibility. The company describes its work as applying AI to cognitive assessment and reducing the manual effort involved in clinical neuropsychology test scoring. The most visible external milestone is selection for Venturelab’s Swiss National Medtech Team 2026, announced on Jun 24, 2026, which offers access to investors and partners through a Boston roadshow. Leadership activity is another possible inflection point: Arnaud Bistoquet began a CEO role on Apr 2, 2026, while Nicolas Langer is also listed as co-founder, CEO, and CSO. That title overlap makes the precise leadership transition unclear. The employee range remains 1–10, and no product launch, customer adoption, hiring outcome, or follow-on investment is specified. The next meaningful indicators of growth would be evidence of clinical validation, implementation with care providers, team expansion, or additional financing.